What is the clinical evidence from this study?

Study design: Review. Population: Heart Disease. Intervention: Ubiquitin-proteasome system (UPS) modulation.

What question did this study set out to answer?

This review aims to explore the impact of the ubiquitin-proteasome system on cardiac health and its therapeutic implications.

August 18, 2014Antioxidants and Redox Signaling

Targeting the Ubiquitin-Proteasome System in Heart Disease: The Basis for New Therapeutic Strategies

View Full Paper

Ask AI

Bookmark

Key result

Modulating the ubiquitin-proteasome system shows therapeutic potential in early cardiac remodeling, but proteasome inhibitors targeting all complexes are associated with cardiotoxicity in humans.

Why the study?

Does modulating the ubiquitin-proteasome system improve outcomes or cause cardiotoxicity in heart disease?

Key Points

This review aims to explore the impact of the ubiquitin-proteasome system on cardiac health and its therapeutic implications.
Reviewed recent advancements in proteasome inhibitors and their effects on cardiac function.
Analyzed the dual role of the ubiquitin-proteasome system in cardiac remodeling and hypertrophy.
Discussed critical issues surrounding the use of proteasome inhibitors in clinical settings.
Proteasome inhibition showed potential in preventing progression and dysfunction in early cardiac disease.
Enhancing proteasome activity improved outcomes in conditions like cardiomyopathies and ischemic injuries.
Toxicity issues were noted with broad proteasome inhibitors, indicating a need for targeted strategies.

Structured PICO

Does modulating the ubiquitin-proteasome system improve outcomes or cause cardiotoxicity in heart disease?

Population

Patients and models with heart disease, heart failure, cardiac remodeling, and pathological hypertrophy

Intervention

Modulation of the ubiquitin-proteasome system (UPS) (e.g., proteasome inhibitors, genetic manipulation, ischemic preconditioning)

Outcome

Cardiac disease progression, contractile dysfunction, and cardiotoxicity

Targeting individual components of the ubiquitin-proteasome system may offer novel therapeutic strategies for heart failure while avoiding the cardiotoxicity associated with broad proteasome inhibitors.

Limitations

Proteasome inhibitors targeting all proteasome complexes are associated with cardiotoxicity in humans.
Type and stage of cardiac disease influence the dynamics of UPS regulation in a nonlinear and multifactorial manner.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Cardiotoxicity limits broad proteasome inhibition; leaves open selective UPS targeting as a research strategy in early remodeling.

Cite This Study

Drews et al. (2014) conducted a review in Heart Disease. Ubiquitin-proteasome system (UPS) modulation was evaluated. Modulating the ubiquitin-proteasome system shows therapeutic potential in early cardiac remodeling, but proteasome inhibitors targeting all complexes are associated with cardiotoxicity in humans.

synapsesocial.com/papers/6a20a3ed01bc09701ff37117 https://doi.org/10.1089/ars.2013.5823

View Full Paper

Ask AI

Bookmark

Targeting the Ubiquitin-Proteasome System in Heart Disease: The Basis for New Therapeutic Strategies

Key Points

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Targeting the Ubiquitin-Proteasome System in Heart Disease: The Basis for New Therapeutic Strategies

Key Points

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Also Consider

Also Consider